MK2 Kinase Degrader Compounds Using E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapeutic agents that can effectively degrade MK2 kinase to treat diseases associated with abnormal cellular responses, such as autoimmune diseases, inflammatory diseases, and cancer, as existing methods are inadequate in controlling the activity of this important intracellular regulator.
Innovation Solution
Development of compounds that act as irreversible degraders of MK2 kinase, specifically designed to bind to an E3 ubiquitin ligase protein, facilitating the degradation of MK2 through the ubiquitin-proteasome pathway, thereby reducing the activity of this kinase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents are used to control MK2 kinase activity, then disease treatment is attempted, but the activity of MK2 kinase cannot be effectively controlled leading to inadequate therapeutic effect
Solution Approach 1:
The patent employs a degrader molecule as an intermediary that bridges the E3 ubiquitin ligase and MK2 kinase. This degrader contains a cereblon-binding moiety that recruits the CRL4^CRBN E3 ubiquitin ligase complex to the MK2 target, facilitating ubiquitination and subsequent proteasomal degradation. This intermediary mechanism enables effective control of MK2 activity that conventional direct inhibitors cannot achieve.
Solution Approach 2:
The invention changes the fundamental parameter of MK2 control from inhibition to degradation. By designing compounds that induce proteasomal degradation rather than simple enzymatic inhibition, the patent achieves more reliable and sustained control of MK2 kinase activity, directly addressing the inadequacy of conventional agents.
2Stability of the object's composition
If MK2 kinase activity is not controlled, then cellular homeostasis is maintained, but abnormal cellular responses lead to diseases such as autoimmune diseases, inflammatory diseases, and cancer
Solution Approach 1:
The patent extracts MK2 kinase from the cellular system through targeted degradation. By using degrader molecules that specifically recruit E3 ubiquitin ligase to MK2, the abnormal protein is removed from the system via the ubiquitin-proteasome pathway, eliminating the source of harmful cellular responses while preserving normal cellular functions.
Solution Approach 2:
The invention converts the harmful overactivity of MK2 kinase into a beneficial therapeutic outcome. By inducing controlled degradation of MK2 through specially designed degrader compounds, the pathogenic cellular responses are eliminated, transforming the problematic kinase activity into a therapeutic mechanism for treating autoimmune diseases, inflammatory diseases, and cancer.
3Ease of manufacture
If existing therapeutic methods are used, then treatment is provided, but they are inadequate for treating conditions like ankylosing spondylitis, rheumatoid arthritis, and psoriasis
Solution Approach 1:
The patent creates a composite therapeutic molecule comprising a cereblon-binding moiety linked to a MK2-targeting warhead. This composite degrader structure combines the recruitment function (binding to CRL4^CRBN E3 ligase) with the target-specific degradation function (binding to MK2), enabling effective treatment of previously refractory diseases like ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively degrade MK2 kinase, leading to therapeutic benefits in treating conditions like ankylosing spondylitis, rheumatoid arthritis, and psoriasis by modulating cytokine production and reducing inflammation.
Implementation Method 1
facilitating the degradation of MK2 through the ubiquitin-proteasome pathway
Data Source
AI summary
The present disclosure provides compounds and compositions useful for degrading MK2 kinase.